Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Jan;57(1):115–116. doi: 10.1038/bjc.1988.22

Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule.

R J Osborne 1, S T Malik 1, M L Slevin 1, V J Harvey 1, J Spona 1, H Salzer 1, C J Williams 1
PMCID: PMC2246673  PMID: 3348944

Full text

PDF
115

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bäckström T., Mählck C. G., Kjellgren O. Progesterone as a possible tumor marker for "nonendocrine" ovarian malignant tumors. Gynecol Oncol. 1983 Aug;16(1):129–138. doi: 10.1016/0090-8258(83)90018-5. [DOI] [PubMed] [Google Scholar]
  2. Hamilton T. C., Davies P., Griffiths K. Androgen and oestrogen binding in cytosols of human ovarian tumours. J Endocrinol. 1981 Sep;90(3):421–431. doi: 10.1677/joe.0.0900421. [DOI] [PubMed] [Google Scholar]
  3. Heinonen P. K., Tuimala R., Pyykkö K., Pystynen P. Peripheral venous concentrations of oestrogens in postmenopausal women with ovarian cancer. Br J Obstet Gynaecol. 1982 Jan;89(1):84–86. doi: 10.1111/j.1471-0528.1982.tb04643.x. [DOI] [PubMed] [Google Scholar]
  4. Holt J. A., Caputo T. A., Kelly K. M., Greenwald P., Chorost S. Estrogen and progestin binding in cytosols of ovarian adenocarcinomas. Obstet Gynecol. 1979 Jan;53(1):50–58. [PubMed] [Google Scholar]
  5. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  6. Myers A. M., Moore G. E., Major F. J. Advanced ovarian carcinoma: response to antiestrogen therapy. Cancer. 1981 Dec 1;48(11):2368–2370. doi: 10.1002/1097-0142(19811201)48:11<2368::aid-cncr2820481105>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  7. Runge H. M., Teufel G., Neulen J., Geyer H., Pfleiderer A. In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy. Cancer Chemother Pharmacol. 1986;16(1):58–63. doi: 10.1007/BF00255287. [DOI] [PubMed] [Google Scholar]
  8. Schwartz P. E., Keating G., MacLusky N., Naftolin F., Eisenfeld A. Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol. 1982 May;59(5):583–588. [PubMed] [Google Scholar]
  9. Shirey D. R., Kavanagh J. J., Jr, Gershenson D. M., Freedman R. S., Copeland L. J., Jones L. A. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol. 1985 Oct;66(4):575–578. [PubMed] [Google Scholar]
  10. Slevin M. L., Harvey V. J., Osborne R. J., Shepherd J. H., Williams C. J., Mead G. M. A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol. 1986 Mar;22(3):309–312. doi: 10.1016/0277-5379(86)90396-2. [DOI] [PubMed] [Google Scholar]
  11. Sutton G. P., Senior M. B., Strauss J. F., Mikuta J. J. Estrogen and progesterone receptors in epithelial ovarian malignancies. Gynecol Oncol. 1986 Feb;23(2):176–182. doi: 10.1016/0090-8258(86)90221-0. [DOI] [PubMed] [Google Scholar]
  12. Wilkinson P. M., Ribiero G. G., Adam H. K., Kemp J. V., Patterson J. S. Tamoxifen (Nolvadex) therapy--radionale for loading dose followed by maintenance dose for patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1982 Dec;10(1):33–35. doi: 10.1007/BF00257234. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES